Insider Transactions in Q1 2025 at Recursion Pharmaceuticals, Inc. (RXRX)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 03
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,569
-0.44%
|
$38,983
$7.25 P/Share
|
|
Feb 03
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
542,092
+15.34%
|
-
|
|
Feb 03
2025
|
Najat Khan Chief R&D Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,753
-0.39%
|
$19,271
$7.25 P/Share
|
|
Feb 03
2025
|
Najat Khan Chief R&D Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
218,162
+12.01%
|
-
|
|
Feb 03
2025
|
Ben R Taylor Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,544
-0.73%
|
$45,808
$7.25 P/Share
|
|
Feb 03
2025
|
Ben R Taylor Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
48,940
+2.68%
|
-
|
|
Jan 10
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.64%
|
$140,000
$7.05 P/Share
|
|
Jan 10
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.58%
|
-
|
|
Jan 08
2025
|
Christopher Gibson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,000
-2.64%
|
$140,000
$7.31 P/Share
|
|
Jan 08
2025
|
Christopher Gibson Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
20,000
+2.58%
|
-
|
|
Jan 02
2025
|
Blake Borgeson Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,734
+0.02%
|
-
|
|
Jan 02
2025
|
Dean Y Li Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,647
+2.08%
|
-
|
|
Jan 02
2025
|
Zavain Dar Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,907
+1.73%
|
-
|